What is HC Wainwright’s Forecast for ARTL FY2025 Earnings?

Artelo Biosciences, Inc. (NASDAQ:ARTL) – Equities research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Artelo Biosciences in a research note issued on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings per share of ($1.84) for the year, down from their previous forecast of ($1.61). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Artelo Biosciences’ current full-year earnings is ($2.62) per share.

A number of other brokerages have also commented on ARTL. D. Boral Capital reiterated a “buy” rating and set a $6.00 price target on shares of Artelo Biosciences in a report on Thursday, February 27th. LADENBURG THALM/SH SH raised shares of Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th.

Artelo Biosciences Stock Performance

Shares of NASDAQ:ARTL opened at $1.00 on Thursday. The stock’s 50-day moving average is $1.17 and its 200-day moving average is $1.15. Artelo Biosciences has a 52-week low of $0.91 and a 52-week high of $1.70. The company has a market cap of $3.23 million, a P/E ratio of -0.35 and a beta of 1.06.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.43).

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.